Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...
Teplizumab has shown significant preservation of C-peptide levels in newly diagnosed type 1 diabetes (T1D) patients, indicating the potential for modifying disease progression. Combining teplizumab ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果